ResMed logo

ResMed (RMD) Q1 2026 Earnings

RMD·Reported April 30, 2026·After market close·FQ3 FY2026

ResMed reported Q1 2026 revenue of $1.4B (+10.8% YoY), beat analyst consensus of $1.4B by $11.5M. Diluted EPS came in at $2.86 (+20.7% YoY), beat the $2.79 consensus by $0.07. ResMed reports across 3 business segments, led by Sleep and Respiratory Care Devices, Masks and Accessories, and Software as a Service (SaaS).

Revenue
$1.4Bbeat by $11.5M
Consensus: $1.4B
Diluted EPS
$2.86beat by $0.07
Consensus: $2.79
SEC

SEC Filings

Earnings release8-K · 0001193125-26-197192
Quarterly report10-Q · 0000943819-26-000025

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2026 Earnings FAQ

Common questions about ResMed's Q1 2026 earnings report.

ResMed (RMD) reported Q1 2026 earnings on April 30, 2026 after market close.

ResMed reported revenue of $1.4B and diluted EPS of $2.86 for Q1 2026.

Revenue beat the consensus estimate of $1.4B by $11.5M. EPS beat the consensus estimate of $2.79 by $0.07.

Compared to the same quarter a year prior, revenue grew 10.8% from $1.3B a year earlier and diluted EPS grew 20.7% from $2.37.

You can read the 8-K earnings release (0001193125-26-197192) and the 10-Q periodic report (0000943819-26-000025) directly on SEC EDGAR. The filing index links above go to sec.gov.